Treatment with dextromethorphan improves endothelial function, inflammation and oxidative stress in male heavy smokers

P. Y. Liu, C. C. Lin, W. C. Tsai, Y. H. Li, L. J. Lin, G. Y. Shi, J. S. Hong, J. H. Chen, Hua Lin Wu

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Dextromethorphan (DM) is reported to reduce the inflammation-mediated degeneration of dopaminergic neurons. Objective: The goal of this study was to test if DM can improve the endothelial dysfunction and inflammatory markers in heavy smokers. Patients and methods: Forty habitual smoking healthy male volunteers (mean age, 31.5±1.4 years) were randomly given either DM (120 mg day-1) or a placebo for 6 months. We determined endothelial function using the brachial artery diameter changes in flow-mediated dilatation (FMD) and measured their inflammatory and oxidative markers. A sex-and-age matched non-smoking group (n = 20) was compared as normal parameters. Results: Habitual smokers showed impaired baseline endothelial function in FMD (smoking vs. non-smoking: 6.3±1.8 vs. 10.2±2.3% respectively, P < 0.01). Without change in smoking behavior, lipid and metabolic parameters, a significant increase in FMD was found in the DM-treated group (32%), accompanied by a decrease in high-sensitivity C-reactive protein (hs-CRP), phospholipase A2, matrix metalloproteinase-3, interleukin 6 (IL-6) and tumor necrosis factor-α receptor II (TNF-α RII) (all P < 0.05), but unchanged in von Willebrand factor (VWF)and plasminogen activator inhibitor-1 (PAI-1). An increase in plasma glutathione peroxidase and a decrease in spot urinary excretion of 8-epi-prostaglandin F2a were found in DM-treated smokers. Conclusions: Our study suggests that a 6-month treatment with DM can improve endothelial function and attenuate vascular oxidative stress and inflammation markers in habitual smokers.

Original languageEnglish
Pages (from-to)1685-1692
Number of pages8
JournalJournal of Thrombosis and Haemostasis
Volume6
Issue number10
DOIs
Publication statusPublished - 2008 Sep 30

Fingerprint

Dextromethorphan
Oxidative Stress
Inflammation
Dilatation
Smoking
Therapeutics
Matrix Metalloproteinase 3
Brachial Artery
Tumor Necrosis Factor Receptors
Phospholipases A2
Dopaminergic Neurons
Plasminogen Activator Inhibitor 1
von Willebrand Factor
Glutathione Peroxidase
C-Reactive Protein
Prostaglandins
Blood Vessels
Interleukin-6
Healthy Volunteers
Placebos

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

@article{aa5f1c408c4140a887701064ddd30b50,
title = "Treatment with dextromethorphan improves endothelial function, inflammation and oxidative stress in male heavy smokers",
abstract = "Background: Dextromethorphan (DM) is reported to reduce the inflammation-mediated degeneration of dopaminergic neurons. Objective: The goal of this study was to test if DM can improve the endothelial dysfunction and inflammatory markers in heavy smokers. Patients and methods: Forty habitual smoking healthy male volunteers (mean age, 31.5±1.4 years) were randomly given either DM (120 mg day-1) or a placebo for 6 months. We determined endothelial function using the brachial artery diameter changes in flow-mediated dilatation (FMD) and measured their inflammatory and oxidative markers. A sex-and-age matched non-smoking group (n = 20) was compared as normal parameters. Results: Habitual smokers showed impaired baseline endothelial function in FMD (smoking vs. non-smoking: 6.3±1.8 vs. 10.2±2.3{\%} respectively, P < 0.01). Without change in smoking behavior, lipid and metabolic parameters, a significant increase in FMD was found in the DM-treated group (32{\%}), accompanied by a decrease in high-sensitivity C-reactive protein (hs-CRP), phospholipase A2, matrix metalloproteinase-3, interleukin 6 (IL-6) and tumor necrosis factor-α receptor II (TNF-α RII) (all P < 0.05), but unchanged in von Willebrand factor (VWF)and plasminogen activator inhibitor-1 (PAI-1). An increase in plasma glutathione peroxidase and a decrease in spot urinary excretion of 8-epi-prostaglandin F2a were found in DM-treated smokers. Conclusions: Our study suggests that a 6-month treatment with DM can improve endothelial function and attenuate vascular oxidative stress and inflammation markers in habitual smokers.",
author = "Liu, {P. Y.} and Lin, {C. C.} and Tsai, {W. C.} and Li, {Y. H.} and Lin, {L. J.} and Shi, {G. Y.} and Hong, {J. S.} and Chen, {J. H.} and Wu, {Hua Lin}",
year = "2008",
month = "9",
day = "30",
doi = "10.1111/j.1538-7836.2008.03082.x",
language = "English",
volume = "6",
pages = "1685--1692",
journal = "Journal of Thrombosis and Haemostasis",
issn = "1538-7933",
publisher = "Wiley-Blackwell",
number = "10",

}

Treatment with dextromethorphan improves endothelial function, inflammation and oxidative stress in male heavy smokers. / Liu, P. Y.; Lin, C. C.; Tsai, W. C.; Li, Y. H.; Lin, L. J.; Shi, G. Y.; Hong, J. S.; Chen, J. H.; Wu, Hua Lin.

In: Journal of Thrombosis and Haemostasis, Vol. 6, No. 10, 30.09.2008, p. 1685-1692.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment with dextromethorphan improves endothelial function, inflammation and oxidative stress in male heavy smokers

AU - Liu, P. Y.

AU - Lin, C. C.

AU - Tsai, W. C.

AU - Li, Y. H.

AU - Lin, L. J.

AU - Shi, G. Y.

AU - Hong, J. S.

AU - Chen, J. H.

AU - Wu, Hua Lin

PY - 2008/9/30

Y1 - 2008/9/30

N2 - Background: Dextromethorphan (DM) is reported to reduce the inflammation-mediated degeneration of dopaminergic neurons. Objective: The goal of this study was to test if DM can improve the endothelial dysfunction and inflammatory markers in heavy smokers. Patients and methods: Forty habitual smoking healthy male volunteers (mean age, 31.5±1.4 years) were randomly given either DM (120 mg day-1) or a placebo for 6 months. We determined endothelial function using the brachial artery diameter changes in flow-mediated dilatation (FMD) and measured their inflammatory and oxidative markers. A sex-and-age matched non-smoking group (n = 20) was compared as normal parameters. Results: Habitual smokers showed impaired baseline endothelial function in FMD (smoking vs. non-smoking: 6.3±1.8 vs. 10.2±2.3% respectively, P < 0.01). Without change in smoking behavior, lipid and metabolic parameters, a significant increase in FMD was found in the DM-treated group (32%), accompanied by a decrease in high-sensitivity C-reactive protein (hs-CRP), phospholipase A2, matrix metalloproteinase-3, interleukin 6 (IL-6) and tumor necrosis factor-α receptor II (TNF-α RII) (all P < 0.05), but unchanged in von Willebrand factor (VWF)and plasminogen activator inhibitor-1 (PAI-1). An increase in plasma glutathione peroxidase and a decrease in spot urinary excretion of 8-epi-prostaglandin F2a were found in DM-treated smokers. Conclusions: Our study suggests that a 6-month treatment with DM can improve endothelial function and attenuate vascular oxidative stress and inflammation markers in habitual smokers.

AB - Background: Dextromethorphan (DM) is reported to reduce the inflammation-mediated degeneration of dopaminergic neurons. Objective: The goal of this study was to test if DM can improve the endothelial dysfunction and inflammatory markers in heavy smokers. Patients and methods: Forty habitual smoking healthy male volunteers (mean age, 31.5±1.4 years) were randomly given either DM (120 mg day-1) or a placebo for 6 months. We determined endothelial function using the brachial artery diameter changes in flow-mediated dilatation (FMD) and measured their inflammatory and oxidative markers. A sex-and-age matched non-smoking group (n = 20) was compared as normal parameters. Results: Habitual smokers showed impaired baseline endothelial function in FMD (smoking vs. non-smoking: 6.3±1.8 vs. 10.2±2.3% respectively, P < 0.01). Without change in smoking behavior, lipid and metabolic parameters, a significant increase in FMD was found in the DM-treated group (32%), accompanied by a decrease in high-sensitivity C-reactive protein (hs-CRP), phospholipase A2, matrix metalloproteinase-3, interleukin 6 (IL-6) and tumor necrosis factor-α receptor II (TNF-α RII) (all P < 0.05), but unchanged in von Willebrand factor (VWF)and plasminogen activator inhibitor-1 (PAI-1). An increase in plasma glutathione peroxidase and a decrease in spot urinary excretion of 8-epi-prostaglandin F2a were found in DM-treated smokers. Conclusions: Our study suggests that a 6-month treatment with DM can improve endothelial function and attenuate vascular oxidative stress and inflammation markers in habitual smokers.

UR - http://www.scopus.com/inward/record.url?scp=52449084260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52449084260&partnerID=8YFLogxK

U2 - 10.1111/j.1538-7836.2008.03082.x

DO - 10.1111/j.1538-7836.2008.03082.x

M3 - Article

C2 - 18647232

AN - SCOPUS:52449084260

VL - 6

SP - 1685

EP - 1692

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

SN - 1538-7933

IS - 10

ER -